Ad-hoc | 22 December 2003 07:31

MorphoSys Forges Therapeutic Antibody Collaboration with Pfizer

Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– MorphoSys Forges Therapeutic Antibody Collaboration with Pfizer MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment) announced today that it has entered into a collaboration with Pfizer Inc for the development of therapeutic antibodies. MorphoSys will use its HuCAL GOLD library to generate therapeutic antibodies against multiple targets from Pfizer. Pfizer will carry out the preclinical and clinical development and the subsequent marketing of resultant products. MorphoSys will receive an upfront payment, which will further strengthen its cash position, and, for each antibody developed in the collaboration, research support and milestone payments. In addition, MorphoSys stands to receive royalty payments, on any antibody products coming out of the collaboration. The potential value to MorphoSys in committed funding and potential developmental milestone payments on future products is in excess of US$ 50 million, not including royalties. During the five-year term of the agreement, MorphoSys will use its HuCAL GOLD antibody technology to select and optimize fully human antibodies against disease targets from Pfizer. MorphoSys brings its expertise in the high- throughput selection and subsequent optimization of fully human antibodies fulfilling predefined criteria to combine with Pfizer’s capabilities for disease target identification and clinical development. end of ad-hoc-announcement (c)DGAP 22.12.2003 Issuer’s information/explanatory remarks concerning this ad-hoc-announcement: About MorphoSys: MorphoSys develops and applies innovative technologies for the production of synthetic antibodies, which accelerate drug discovery and target characterization. Founded in 1992, the Company’s proprietary Human Combinatorial Antibody Library (HuCALâ) technology is used by researchers worldwide for human antibody generation. The Company currently has licensing and research collaborations with Bayer (Berkeley, California/USA), Biogen Inc. (Cambridge, Massachusetts/USA), Boehringer Ingelheim (Ingelheim, Germany), Bristol-Myers Squibb (Wilmington, Delaware/USA), Centocor Inc. (Malvern, Pennsylvania/USA), California/USA), GPC Biotech AG (Munich/Germany), Hoffmann-La Roche AG (Basel/Switzerland), ImmunoGen Inc. (Cambridge, Massachusetts/USA), Oridis Biomed GmbH (Graz/Austria), Pfizer Inc. (Delaware/USA), ProChon Biotech Ltd. (Rehovot/Israel), Schering AG (Berlin/Germany) and Xoma Ltd. (Berkeley, California/USA). For further information please visit the corporate website at: http://www.morphosys.com/. For more information, please contact MorphoSys: Dr. Claudia Gutjahr-Löser, Manager Corporate Communications, Tel. +49 (0)89 89927 122, gutjahr@morphosys.com ——————————————————————————– WKN: 663200; ISIN: DE0006632003; Index: Nemax 50 Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 220731 Dez 03